Medivir: IMbrave251 Validates Medivir’s Second-Line Positioning - Redeye

Final data from the second-line phase III study in liver cancer were presented in an oral abstract session at ASCO last week. They demonstrated that second-line checkpoint inhibitor therapy is unlikely to be successful, leaving a significant market opportunity open for fostrox.

Länk till analysen i sin helhet: https://www.redeye.se/research/1169314/medivir-imbrave251-validates-medivirs-second-line-positioning?utm_source=finwire&utm_medium=RSS